Escitalopram

Generic Name
Escitalopram
Brand Names
Cipralex, Lexapro
Drug Type
Small Molecule
Chemical Formula
C20H21FN2O
CAS Number
128196-01-0
Unique Ingredient Identifier
4O4S742ANY
Background

Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic citalopram. It is used to restore serotonergic function in the treatment of depression and anxiety. Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with...

Indication

Escitalopram is indicated for the acute and maintenance treatment of major depressive disorder (MDD) in adults and pediatric patients 12 years old and older and for the acute treatment of generalized anxiety disorder (GAD) in adults and pediatric patients 7 years old and older. It is additionally indicated for symptomatic relief of obsessive-compulsive disor...

Associated Conditions
Anxiety, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD)
Associated Therapies
-
Clinical Trials
Related News
wxow.com
·

What experts say about taking psilocybin as an alternative treatment for depression

Psilocybin, the active ingredient in 'magic mushrooms,' is compared to the antidepressant escitalopram in a six-month trial for depression. Psilocybin showed greater flexibility in brain states and higher well-being scores, but both treatments had comparable depressive symptom improvements. Critics argue for more extensive trials and addressing issues like cost and patient selection before widespread use.

Related Clinical Trials:

Psilocybin for the Treatment of Cluster Headache
globenewswire.com
·

Anxiety Disorders and Depression Treatment Market to Reach

The Anxiety Disorders and Depression Treatment Market was valued at USD 12.2 billion in 2023 and is projected to reach USD 16.65 billion by 2032, growing at a CAGR of 3.53%. This growth is driven by the rising prevalence of anxiety disorders and depression, advancements in pharmaceutical therapies, and increased awareness and destigmatization of mental health issues.
wsiltv.com
·

Psilocybin: Searching for the antidepressant of the future

Psilocybin vs. escitalopram in treating depression: Psilocybin showed greater joy and well-being at six months, but challenges remain in scaling and cost. Brain scans revealed increased flexibility in psilocybin users, predicting better outcomes.

Related Clinical Trials:

Psilocybin for the Treatment of Cluster Headache
sandiegouniontribune.com
·

Danish pharma giant buys San Diego company's epilepsy drug for $2.6B

Lundbeck to acquire Longboard Pharmaceuticals for $2.6 billion, gaining access to its novel epilepsy drug, bexicaserin, which targets 5-HT2C receptors and has FDA breakthrough therapy designation. The deal, Lundbeck's largest, aims to address unmet needs in rare and severe epilepsies, with bexicaserin expected to launch by 2028 with potential sales of $1.5-$2 billion.
ttownmedia.com
·

Could Antidepressants Give Memory a Boost? | Health

Antidepressants like escitalopram may boost cognitive function via the 5HT4 receptor, improving memory and thinking skills.
drugs.com
·

Psilocybin Equals or Exceeds SSRI Antidepressants at Easing Depression

Psilocybin, in magic mushrooms, shows similar depression relief to SSRI antidepressants like Lexapro, with additional long-term benefits of greater life meaning and psychological connectedness, according to a clinical trial. However, psilocybin is experimental and should not be self-administered.
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy